GATC Health Corp, a pioneer in AI-driven drug discovery and disease prediction, has achieved a significant milestone. According to a recent MarketWatch article, the University of California, Irvine (UCI) has independently verified GATC Health’s AI platform’s ability to predict drug efficacy, safety, and off-target effects.
Key Findings
- GATC’s AI platform demonstrated a true positive rate of 91% (Specificity Test) and a true negative rate of 86% (Sensitivity Test) in predicting outcomes for early-stage drug candidates.
- These results further validate GATC’s AI platform’s capability to effectively measure key indicators of successful phase 1 and phase 2 clinical trials.
- The external validation by UCI confirmed, and in some cases exceeded, GATC’s internal retrospective double-blinded analysis from September 2023.
AI Screening Process
GATC’s AI screening process comprises three crucial steps:
- Safety Screening: Uses AI predictions to screen for toxic or negative activation on biological targets, assessing safety and potential side effects.
- Efficacy Screening: Employs AI predictions to screen for positive activation on intended and unintended targets, evaluating efficacy and secondary side effects.
- Optimized Screening: Utilizes AI predictions after acquiring knowledge about the researched molecules, often outperforming blind, verified outcomes.
Methodology and Results
- The UCI tests involved over 4,600 molecules across two separate tests.
- GATC received only the chemistry of the molecules before providing predictions on predetermined biological targets.
- The tests rigorously adhered to GATC Health’s screening process, with molecules and their activity known only to the UCI lab.
Potential Impact
According to Dr. Tomas Philipson, former Acting Chairman of the White House Council of Economic Advisers and advisor to GATC Health, this breakthrough could provide pharmaceutical companies and investors with a vital tool for making billion-dollar decisions. The platform’s ability to predict drug success and safety risks could significantly reduce costs and risks associated with drug development.
Future Implications
GATC Health’s validated AI platform has the potential to revolutionize the drug discovery landscape by:
- Expediting and optimizing the drug discovery process
- Reducing the risk and cost associated with drug development
- Potentially leading to faster development of new therapies for patients globally
For more details, we encourage you to read the full article on MarketWatch: “University of California, Irvine, Verifies GATC Health’s Ability to Predict Drug Efficacy, Safety and Off-target Effects”
